GeoVax Labs, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. The company is a clinical-stage biotechnology business developing vaccines and immunotherapies using its MVA-VLP platform. Reported revenue is from grants and research collaborations, not commercial product sales.
Financial results and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Grant and collaboration revenue | $440,602 | $209,941 | $1,156,579 | $574,173 |
| Research and development expense | $461,421 | $451,227 | $1,270,357 | $1,006,945 |
| General and administrative expense | $427,292 | $412,650 | $929,637 | $922,714 |
| Operating loss | $(448,111) | $(653,936) | $(1,043,415) | $(1,355,486) |
| Net loss | $(455,204) | $(654,148) | $(1,050,898) | $(1,355,602) |
- Revenue increased year over year, reflecting higher grant and collaboration activity. Six-month R&D expense rose 26%, primarily due to the timing and amount of grant-related expenditures.
- At June 30, cash and cash equivalents were $710,682, versus $283,341 at year-end 2019. Working capital was negative $1,847,550; total assets were $957,943, total liabilities $2,807,564, and stockholders’ equity was negative $1,849,621.
- Six-month operating cash use was $925,493, compared with $773,809 in 2019. Financing provided $1,352,834, including preferred-stock proceeds, a PPP loan, and bridge financing.
- Current liabilities included $435,711 carrying value of convertible debentures and $182,379 of current notes payable. The company reported $1,972,073 in deferred management salaries and director fees, included in accrued expenses.
Financing, material changes, and outlook
- In June, GeoVax received $1,050,000 gross proceeds from a secured bridge financing, issuing $1,200,000 principal amount of 5% convertible debentures and five-year warrants for 2,400,000 shares at $0.50 per share. Net proceeds were $888,500. The debentures mature in 12 months, are secured by substantially all company assets, and become convertible after six months; conversion terms include a price adjustment linked to a qualifying public offering.
- The company received a $170,200 PPP loan at 1% interest. GeoVax intends to seek forgiveness or reduction based on eligible expenses; forgiveness is not assured.
- Preferred-stock conversions in the first quarter resulted in 13,481,349 common shares issued. The January 2020 one-for-2,000 reverse split and the prior reverse split make historical per-share figures and share counts important to interpret carefully. The filing reports 15,436,913 common shares outstanding as of August 10, 2020.
- Management said existing cash and government and collaborative funding commitments were expected to support planned operations into Q4 2020. The company needs additional capital thereafter and was pursuing grants, collaborations, and an equity offering. Management stated that substantial doubt about the company’s ability to continue as a going concern was not alleviated.
- Approved grant funding available through September 2021 was $650,051; approximately $184,100 of collaboration fees were expected to become billable. The company expects grant-reimbursed vendor commitments of approximately $400,834.
- COVID-19 could delay planned HIV clinical programs. Management does not provide forward cost or completion estimates for research programs; development, regulatory approval, and financing remain uncertain. No material changes to previously disclosed risk factors were reported.
- After quarter-end, holders converted all 300 Series J preferred shares into 854,458 common shares, and cashless warrant exercises resulted in 738,048 additional common shares.
Investor verification priorities
- Confirm the timing, terms, and availability of additional financing, and reassess cash runway and the going-concern risk.
- Review the secured debentures’ maturity, conversion and offering provisions, warrant dilution, and the effects of price-adjustment clauses.
- Track payment or potential equity settlement of the $1,972,073 in deferred salaries and director fees, as well as vendor commitments and PPP loan treatment.
- Verify grant reimbursements, collaboration billings, and whether anticipated clinical programs proceed or are delayed.
- Reconcile post-quarter share issuances and reverse-split-adjusted share data when assessing dilution and per-share comparisons.